Mineral and bone disorder in Chinese dialysis patients: a multicenter study

Xianglei Kong, Luxia Zhang, Ling Zhang, Nan Chen, Yong Gu, Xueqing Yu, Wenhu Liu, Jianghua Chen, Liren Peng, Weijie Yuan, Hua Wu, Wei Chen, Minhua Fan, Liqun He, Feng Ding, Xiangmei Chen, Zuying Xiong, Jinyuan Zhang, Qiang Jia, Wei Shi, Changying Xing, Xiaoling Tang, Fanfan Hou, Guiyang Shu, Changlin Mei, Li Wang, Dongmei Xu, Zhaohui Ni, Li Zuo, Mei Wang, Haiyan Wang, Xianglei Kong, Luxia Zhang, Ling Zhang, Nan Chen, Yong Gu, Xueqing Yu, Wenhu Liu, Jianghua Chen, Liren Peng, Weijie Yuan, Hua Wu, Wei Chen, Minhua Fan, Liqun He, Feng Ding, Xiangmei Chen, Zuying Xiong, Jinyuan Zhang, Qiang Jia, Wei Shi, Changying Xing, Xiaoling Tang, Fanfan Hou, Guiyang Shu, Changlin Mei, Li Wang, Dongmei Xu, Zhaohui Ni, Li Zuo, Mei Wang, Haiyan Wang

Abstract

Background: Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patients are extremely limited.

Methods: A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD) patients were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), intact parathyroid hormone (iPTH) were analyzed. The achievement of MBD targets was compared with the results from the Dialysis Outcomes and Practice Study (DOPPS) 3 and DOPPS 4. Factors associated with hyperphosphatemia were examined.

Results: Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%, 39.6% and 26.6% of them met the Kidney Disease Outcomes Quality Initiative (K/DOQI) defined targets for serum P, Ca and iPTH levels. Serum P and Ca levels were statistically higher (P < 0.05) in the HD patients compared with those of PD patients, which was (6.3 ± 2.1) mg/dL vs (5.7 ± 2.0) mg/dL and (9.3 ± 1.1) mg/dL vs (9.2 ± 1.1) mg/dL, respectively. Serum iPTH level were statistically higher in the PD patients compared with those of HD patients (P = 0.03). The percentage of patients reached the K/DOQI targets for P (37.6% vs 49.8% vs 54.5%, P < 0.01), Ca (38.6% vs 50.4% vs 56.0%, P < 0.01) and iPTH (26.5% vs 31.4% vs 32.1%, P < 0.01) were lower among HD patients, compared with the data from DOPPS 3 and DOPPS 4. The percentage of patients with serum phosphorus level above 5.5 mg/dL was 57.4% in HD patients and 47.4% in PD patients. Age, dialysis patterns and region of residency were independently associated with hyperphosphatemia.

Conclusions: Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue of hyperphosphatemia is prominent and needs further attention.

Figures

Figure 1
Figure 1
A map marked with study centers.

References

    1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218. doi: 10.1097/01.ASN.0000133041.27682.A2.
    1. Hruska KA, Saab G, Mathew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial. 2007;20(4):309–315. doi: 10.1111/j.1525-139X.2007.00300.x.
    1. Palmer SC, Hayen A, Macaskill P. et al.Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119–1127. doi: 10.1001/jama.2011.308.
    1. Levin A, Bakris GL, Molitch M. et al.Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–38. doi: 10.1038/sj.ki.5002009.
    1. Gutierrez O, Isakova T, Rhee E. et al.Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205–2215. doi: 10.1681/ASN.2005010052.
    1. Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Am J Kidney Dis. 2007;49(2):257–266. doi: 10.1053/j.ajkd.2006.11.027.
    1. Tentori F. Mineral and bone disorder and outcomes in hemodialysis patients: results from the DOPPS. Semin Dial. 2010;23(1):10–14. doi: 10.1111/j.1525-139X.2009.00676.x.
    1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003. pp. S1–S201.
    1. Dialysis Outcomes and Practice Patterns Study. DOPPS annual report. 2010. .
    1. Kalantar-Zadeh K, Kuwae N, Regidor DL. et al.Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–780. doi: 10.1038/sj.ki.5001514.
    1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617. doi: 10.1053/ajkd.1998.v31.pm9531176.
    1. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1(4):825–831. doi: 10.2215/CJN.02101205.
    1. Kovesdy CP, Kalantar-Zadeh K. Serum phosphorus and the risk of progression of chronic kidney disease. Nephrol Dial Transplant. 2007;22(12):3679–3680. doi: 10.1093/ndt/gfm539.
    1. Zhao L, Stamler J, Yan LL. et al.Blood pressure differences between northern and southern Chinese: role of dietary factors: the International Study on Macronutrients and Blood Pressure. Hypertension. 2004;43(6):1332–1337. doi: 10.1161/01.HYP.0000128243.06502.bc.
    1. Walsh M, Manns BJ, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. Hemodial Int. 2010;14(2):174–181. doi: 10.1111/j.1542-4758.2009.00418.x.
    1. Pierratos A, Ouwendyk M, Francoeur R. et al.Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol. 1998;9(5):859–868.
    1. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol. 2005;16(9):2778–2788. doi: 10.1681/ASN.2005040392.
    1. Maduell F, Navarro V, Torregrosa E. et al.Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int. 2003;64(1):305–313. doi: 10.1046/j.1523-1755.2003.00043.x.
    1. Tonelli M, Wang W, Hemmelgarn B, Lloyd A, Manns B. Phosphate removal with several thrice-weekly dialysis methods in overweight hemodialysis patients. Am J Kidney Dis. 2009;54(6):1108–1115. doi: 10.1053/j.ajkd.2009.05.018.
    1. Penne EL, van der Weerd NC, van den Dorpel MA. et al.Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST) Am J Kidney Dis. 2010;55(1):77–87. doi: 10.1053/j.ajkd.2009.09.023.
    1. Melamed ML, Eustace JA, Plantinga L. et al.Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006;70(2):351–357. doi: 10.1038/sj.ki.5001542.
    1. Wald R, Sarnak MJ, Tighiouart H. et al.Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis. 2008;52(3):531–540. doi: 10.1053/j.ajkd.2008.05.020.
    1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2009. pp. S1–S130.
    1. Soroka SD, Beard KM, Mendelssohn DC, Cournoyer SH, Da Roza GA, Geary DF. Mineral metabolism management in Canadian peritoneal dialysis patients. Clin Nephrol. 2011;75(5):410–415.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する